Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. - Wikidata - awgldk - TriplyDB

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

http://www.wikidata.org/entity/Q44298535

about

Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Kinetics of neutrophils in mice exposed to radiation and/or granulocyte colony-stimulating factor treatment.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)Modelling chemotherapy effects on granulopoiesis.Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma.Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.The use of granulocyte colony-stimulating factors in a Canadian outpatient setting.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and com Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

P2860

Q24632145-FE581EB9-128E-4801-9793-CF9FC209771E Q27008080-41287DB9-D79B-4203-AE95-ACF2AFE6D55E Q33383573-162D0165-6CC8-4D68-8DC7-6999410537CD Q33712928-DBAF4A9A-4BC3-48CF-A626-08A6539F0C69 Q34020253-EDAC89BC-9F97-4695-83A8-0E4273994C6D Q34029496-118C2606-58B5-4FE9-B5EC-F79A97347317 Q34343470-A968DC29-DF13-4B3C-82EB-54BE4A4953D4 Q34353567-ED025093-6788-4AE1-8729-FDB02A72090D Q34539360-69B4B58E-EF74-4EBF-AFD4-8E64A7A75128 Q34996295-F190331E-231D-4741-84C2-C46E59E50EE8 Q35200824-D33FA0A7-E7B1-460C-9DF6-81A9FE985A9A Q35808451-E54A3254-B5F5-4DDE-88D5-6E424B55B53D Q35860879-D511FD04-5B09-404C-A925-45273107FE2F Q35998006-BF6AE92F-FD6C-4213-B240-729EAD7C667E Q36103329-E934BDA0-8C79-46A4-92F8-216A1AE1D08C Q36235531-E2D5599D-96F3-4DD5-AD53-17CE3822FCF6 Q36327074-2B7A94E1-F677-4755-A4B6-00579C584858 Q36427261-B0E9B5F4-517E-43E2-82ED-801067A66E4C Q36485208-8DDAD86C-68C9-467E-BC19-1135953F2B97 Q36677460-5378119E-1D48-4A02-9928-CA00356C7C1E Q37241723-4E69779B-6941-422C-B275-E6355FF633B5 Q37321114-18660C42-E042-46DD-B28A-10381DFAF276 Q37357347-317FDE98-F48D-4BDA-AA25-F5976A06DE1F Q37421288-48626D89-5077-4605-97CC-5665BC354951 Q37606891-F5359A98-ABC4-4C44-9E89-3AA052679E39 Q37719624-5D9E3A1D-D469-47E1-B74A-200C07DE173B Q38072290-62A4F63C-E972-4E5D-859D-30EA7DF5F8E3 Q38193590-39418279-F375-401E-B2D5-6E5021C0D3F3 Q38269589-8F8E40B9-A4F3-489A-99B1-DA865F165F58 Q38608267-2B453F40-DCDA-4029-A8A6-621E51B638E4 Q39782796-9282CE02-C8D6-4165-8B00-812140031FB0 Q40147851-C6EEA050-8465-48C5-A623-C9AA08C870A6 Q40163155-137FBFF9-7F3A-4070-AE04-B3249E27B4D8 Q40240657-9164AD7D-853E-4C85-95FF-8726B59B34B2 Q40346049-41A8F8E8-482E-46AC-B3A9-3B583E68125F Q40489362-72A93DEC-DC31-4AB1-8CB8-56788432AE5A Q40513157-26F9386F-9B22-41CA-98FB-9CB79B8992D5 Q42223844-669BFBE0-E555-4231-BC39-D4AC522B3D69 Q42363042-F8C8AA1E-62A7-4B56-8DBA-8A9A7D517D24 Q42540897-C891AA41-D945-44F2-B4A8-D6F0D3ADC0E7

P2860

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

http://www.wikidata.org/entity/Q44298535

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@en

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@nl

type

label

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@en

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@nl

prefLabel

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@en

Randomized, multicenter, open- ...... ter chemotherapy for lymphoma.

@nl

P1433

Q44298535-E496DA95-E99A-451B-90A7-C587B0C79092

P1476

Q44298535-854C5390-0994-40F7-9D91-5B3344AF2F04

P2093

Q44298535-026BD88F-38D3-4024-A50B-51FF79600EE9

Q44298535-0C873451-F4F7-4760-A653-7B634D9A275F

Q44298535-1A0BE261-BF70-462E-8003-390D6BCCE5DD

Q44298535-1E95F16F-5AED-4B29-94A4-8F0C4355D71F

Q44298535-210201F0-7950-4D9B-BA71-20E746E412EC

Q44298535-23AE299B-EB56-40E6-8A81-7C01BBAB12FC

Q44298535-4E3FC5D2-E855-495D-B3B9-0F27F036F621

Q44298535-5FA6FC78-3527-49FA-9E09-14E9B8C23A7F

Q44298535-91F62232-C017-41E1-AA02-17F759C78A9B

Q44298535-FF8C6953-B5C8-4166-BBF0-D3C6EF5727B6

P304

Q44298535-950A1B44-5C92-4BD2-9645-60E1867981EC

P31

Q44298535-83C96D0D-BA87-40F8-888B-29D05513F99A

P356

Q44298535-3D2BC3EE-7B31-45C2-A4AD-587B148C767C

P407

Q44298535-78E9FBF1-F143-4724-BB3C-34ADA2C502C1

P433

Q44298535-52A32D8D-65EC-4D7C-B1E4-B446336AB897

P478

Q44298535-6FA2EF82-DEF9-40AA-92C2-DA956D7DAF7C

P50

Q44298535-6BE1BBF3-D6C4-44CF-ADB1-EDC14A74E309

P577

Q44298535-B91C8E69-9781-461D-A616-470B870A6178

P698

Q44298535-A3D3EBB3-8526-45D1-A2D3-C06F9F3AEFCD

P921

Q44298535-C1198C21-3604-4F64-9FD9-41859B58B90C

P356

JCO.2003.03.040

P1433

Journal of Clinical Oncology

P1476

Randomized, multicenter, open- ...... fter chemotherapy for lymphoma

@en

P2093

B C Liang

http://www.w3.org/2001/XMLSchema#string

C Emmanouilides

http://www.w3.org/2001/XMLSchema#string

D Schenkein

http://www.w3.org/2001/XMLSchema#string

H Lazarus

http://www.w3.org/2001/XMLSchema#string

J Hackett

http://www.w3.org/2001/XMLSchema#string

J M Vose

http://www.w3.org/2001/XMLSchema#string

J Moore

http://www.w3.org/2001/XMLSchema#string

M Crump

http://www.w3.org/2001/XMLSchema#string

S Frankel

http://www.w3.org/2001/XMLSchema#string

W Lovelace

http://www.w3.org/2001/XMLSchema#string

P304

514-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.03.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12560443

http://www.w3.org/2001/XMLSchema#string

P921